MaaT Pharma Presents New Data on MaaT034 at SITC Congress
MaaT Pharma revealed preclinical results for its drug candidate MaaT034 at the annual congress of the Society for Immunotherapy of Cancer (SITC), according to a company press release.
Development and Mechanism of MaaT034
According to MaaT Pharma, MaaT034, which is under development, is designed to enhance patients' responses to immunotherapies in combination with immune checkpoint inhibitors. The company relies on its MET-C co-culture technology, which uses artificial intelligence to produce synthetic microbial ecosystems on a large scale without the need for donors. The drug enhances T lymphocyte activation and improves the efficacy of existing treatments in preclinical models. Additionally, two exploratory clinical trials are underway with the products MaaT013 and MaaT033 for various oncology indications.
Significance of the SITC Congress and Future Plans
The SITC congress is a major global event for advancements in cancer immunotherapy. At this event, the results for MaaT034 demonstrated successful implantation in axenic mice and optimization of the immune response in combination with PD-1 immune checkpoint inhibition. MaaT Pharma plans future clinical trials for MaaT034, while also preparing for participation in other significant conferences such as the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire and Investir Day. According to the company, these developments aim to enhance the impact of MaaT034 on oncology.
